As of November 10, 2026, Abeona Therapeutics Inc. is a publicly traded company (Nasdaq: ABEO). The largest holder reporting an active stake on Schedule 13D is James Russell Revocable Trust, at 6.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Nantahala Capital (9.99%), Nantahala Capital Partners Limited Partnership (5.82%), Orin Hirschman (5.4%) (Schedule 13D, October 23, 2026).
Is this your company?
About to sign with, pay or invest in Abeona Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Abeona Therapeutics Inc. a real, registered company?
- Abeona Therapeutics Inc. files with the SEC under CIK 318306 (its SEC filings).
- Its shares are listed under the ticker ABEO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cleveland, Ohio, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ABEONA THERAPEUTICS INC. in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Michael Amoroso, Director (Form 8-K filed 2026-06-12). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names James Russell Revocable Trust (filed 2026-10-23).
Who are Abeona Therapeutics Inc.'s owners and officers?
Abeona Therapeutics Inc.: incorporated in Delaware; business address in Cleveland, Ohio; industry Pharmaceutical Preparations (Form 8-K, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-10-23 | James Russell Revocable Trust | 6.1% |
| Schedule 13G/A, 2026-08-14 | Montanova Capital, LLC | 0.9% |
| Schedule 13G/A, 2026-05-15 | Nantahala Capital Partners Limited Partnership | 5.82% |
| Schedule 13G/A, 2026-05-15 | Nantahala Capital Management, LLC | 9.99% |
| Schedule 13G, 2026-04-28 | Orin Hirschman | 5.4% |
| Schedule 13G, 2026-04-06 | Funicular Funds, LP | 5.3% |
| Schedule 13G, 2026-03-27 | Daniel Kaufman | 5.16% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-12 | Adage Capital Management, L.P. | 0% |
| Schedule 13G/A, 2025-11-13 | Adage Capital Management, L.P. | 9.99% |
| Schedule 13G, 2025-10-30 | The Vanguard Group | 5.07% |
| Schedule 13G, 2025-10-06 | Nantahala Capital Partners Limited Partnership | 5.09% |
Questions about who owns Abeona Therapeutics Inc.
Who owns Abeona Therapeutics Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Abeona Therapeutics Inc.: Nantahala Capital Management, LLC (9.99%, Schedule 13G/A, filed 2026-05-15), James Russell Revocable Trust (6.1%, Schedule 13D, filed 2026-10-23), Nantahala Capital Partners Limited Partnership (5.82%, Schedule 13G/A, filed 2026-05-15), Orin Hirschman (5.4%, Schedule 13G, filed 2026-04-28) and Funicular Funds, LP (5.3%, Schedule 13G, filed 2026-04-06); 1 more is listed above.
Who are the largest shareholders of Abeona Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Abeona Therapeutics Inc. on this page are Nantahala Capital Management, LLC (9.99%), James Russell Revocable Trust (6.1%) and Nantahala Capital Partners Limited Partnership (5.82%).
When did Nantahala Capital Management, LLC buy into Abeona Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Nantahala Capital Management, LLC on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Abeona Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Abeona Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Abeona Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-12 | Michael Amoroso | Director | departed | |
| Form 8-K, 2026-06-12 | Michael Amoroso | departed | ||
| Form 8-K, 2026-04-07 | Keith A. Goldan | Director | appointed | |
| Form 8-K, 2026-04-07 | Keith A. Goldan | appointed |
Which insiders own Abeona Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,286,500 shares (2.3% of shares outstanding) (Form 4, 2026-09-29).
- , the chief financial officer: 482,888 shares (0.84% of shares outstanding) (Form 4, 2026-09-29).
- , the senior vice president and chief legal officer: 421,226 shares (0.74% of shares outstanding) (Form 4, 2026-09-29).
- , the chief commercial officer: 285,721 shares (0.50% of shares outstanding) (Form 4, 2026-09-29).
- , a director: 217,779 shares (0.38% of shares outstanding) (Form 4, 2026-01-27).
Shares outstanding: 57,146,840 as of 2026-11-05, from the company's latest SEC cover page.
How much has Abeona Therapeutics Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-11-09).
Keep reading
More on Abeona Therapeutics Inc. and the records around it.
Abeona Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jun 2026
Companies that share a holder
- Daniel Kaufman also filed stake reports on 6 other companies: AUNA S.A. (May 2026), DELCATH SYSTEMS, INC. (Mar 2026), i-80 Gold Corp. (Jan 2026)
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), KIORA PHARMACEUTICALS, INC. (May 2026)
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/abeona-therapeutics